Organisation paid for research Program year 2025 Source: CMS Open Payments

Le Bonheur Children's Hospital Foundation

Neither a doctor nor a teaching hospital

Research payments

$808,652

273 payments

Through program year 2025, Le Bonheur Children's Hospital Foundation is reported as receiving $808,652 in research payments, across 273 payments.

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$69,245	48
2024	Research	$263,153	52
2023	Research	$242,338	93
2022	Research	$161,528	41
2021	Research	$40,477	19
2020	Research	$31,910	20

Breakdown

Who paid Research payments · program years 2020–2025

SK Life Science, Inc. $321,577 113 payments
Takeda Pharmaceuticals U.S.A., Inc. $190,055 54 payments
Marinus Pharmaceuticals, Inc. $73,893 20 payments
Neurelis, Inc. $60,289 8 payments
AveXis $40,126 16 payments
CSL Behring $26,791 21 payments
CutisPharma, Inc. $21,250 7 payments
Zogenix Inc. $20,732 1 payment
American Regent $20,035 1 payment
Aimmune Therapeutics, Inc. $17,046 21 payments

Studies the money was for Research payments · program years 2020–2025

Phase 3, Multicenter, Randomized Study With 2 Different Doses of Prucalopride Administered to Male and Female Pediatric Subjects Aged 6 Months to 17 Years With Functional Constipation, Consisting of A 12-Week Double-Blind, Placebo-Controlled Part (Part A) to Evaluate Efficacy and Safety Followed By A 36-Week Double-Blind Extension Part (Part B) to Document Long-Term Safety Up to Week 48 $190,055 54 payments
Ykp3089c039 $116,586 29 payments
Ykp3089c040 $94,445 46 payments
Ykp3089c039 $81,837 24 payments
An Open-Label, Single-Dose, Pharmacokinetics Study of Valtoco With Open-Label Safety Period in Pediatric Subjects With Epilepsy $60,289 8 payments
A Prospective, Long-Term Registry of Patients with a Diagnosis of Spinal Muscular Atrophy $40,126 16 payments
A Phase 3, Open-label Study of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults With Tuberous Sclerosis Complex (TSC)-Related Epilepsy (TrustTSC OLE) $38,999 16 payments
A Phase 3, Double-blind, Randomized, Placebo-controlled Trial of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults With Tuberous Sclerosis Complex (TSC)-Related Epilepsy (TrustTSC) $34,894 4 payments
Randomized Study of Single vs. Multiple Privigen Dose Regimens in Pediatric CIDP $26,791 21 payments
Ykp3089c025 $22,350 12 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.